PTX-100 Ph1b results show excellent safety & efficacy in TCL
Filed with ASX · · 6 pages · English
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- September 2023 Quarterly Update and Appendix 4C
- Appendix 4E and 2023 Annual Report
- June 2023 Quarterly Update and Appendix 4C
- March 2023 Quarterly Update and Appendix 4C
- Continued promising results in PTX-100 TCL trial
Later from Prescient Therapeutics
- December 2023 Quarterly Update and Appendix 4C
- March 2024 Quarterly Update and Appendix 4C
- June 2024 Quarterly Update and Appendix 4C
- Appendix 4E and 2024 Annual Report
- Prescient CEO to step down in early 2025
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics